IP Library › Granted Patent US 9,481,639
Granted Patent B2
US 9,481,639 · App. 13/987,655 · Granted Nov 1, 2016

Substituted tetracycline compounds for treatment of inflammatory skin disorders

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,481,639
App. No.
13/987,655
Granted
Nov 1, 2016
Kind
B2
Abstract

Methods and compositions for the treatment of skin disorders (e.g., acne, rosacea) are described.

Claims (12)

1. A method for treating a subject suffering from acne, comprising administering to the subject an effective amount of a substituted tetracycline compound that is

or a pharmaceutically acceptable salt thereof.

2. A method for treating a subject suffering from rosacea, comprising administering to the subject an effective amount of a substituted tetracycline compound that is

or a pharmaceutically acceptable salt thereof.

3. The method according to claim 1 , wherein the amount of substituted tetracycline compound administered to the subject is in a range of from 0.01 to 100 milligrams per kilogram of body weight of the subject.

4. The method according to claim 2 , wherein the amount of substituted tetracycline compound administered to the subject is in a range of from 0.01 to 100 milligrams per kilogram of body weight of the subject.

5. The method according to claim 1 , wherein the amount of substituted tetracycline compound administered to the subject is in a range of from 0.1 to 50 milligrams per kilogram of body weight of the subject.

6. The method according to claim 2 , wherein the amount of substituted tetracycline compound administered to the subject is in a range of from 0.1 to 50 milligrams per kilogram of body weight of the subject.

7. The method according to claim 1 , wherein the amount of substituted tetracycline compound administered to the subject is in a range of from 1 to 20 milligrams per kilogram of body weight of the subject.

8. The method according to claim 2 , wherein the amount of substituted tetracycline compound administered to the subject is in a range of from 1 to 20 milligrams per kilogram of body weight of the subject.

9. The method according to claim 1 , wherein the subject is a human.

10. The method according to claim 2 , wherein the subject is a human.

Assignments (8)
RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL/FRAME 71200/0656 Recorded Mar 17, 2026
From: OAKTREE FUND ADMINISTRATION, LLC
To: PARATEK PHARMACEUTICALS, INC.
Reel/Frame 075101/0815 →
PATENT SECURITY AGREEMENT Recorded Mar 16, 2026
From: PARATEK PHARMACEUTICALS, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 075111/0244 →
SECURITY INTEREST Recorded May 22, 2025
From: PARATEK PHARMACEUTICALS, INC.
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 071200/0656 →
RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL/FRAME 065001/0917 Recorded May 22, 2025
From: OAKTREE FUND ADMINISTRATION, LLC
To: PARATEK PHARMACEUTICALS, INC.
Reel/Frame 071343/0407 →
SECURITY INTEREST Recorded Sep 22, 2023
From: PARATEK PHARMACEUTICALS, INC.
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 065001/0917 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 7, 2014
From: ASSEFA, HAREGEWEIN; BHATIA, BEENA; DRAPER, MICHAEL; HONEYMAN, LAURA; KIM, OAK K.; MOLNAR, DENNIS P.
To: PARATEK PHARMACEUTICALS, INC.
Reel/Frame 034123/0959 →
RELEASE OF SECURITY INTEREST Recorded Oct 31, 2014
From: HBM HEALTHCARE INVESTMENTS (CAYMAN) LTD., AS COLLATERAL AGENT
To: PARATEK PHARMACEUTICALS, INC.
Reel/Frame 034113/0910 →
SECURITY INTEREST Recorded Mar 14, 2014
From: PARATEK PHARMACEUTICALS, INC.
To: HBM HEALTHCARE INVESTMENTS (CAYMAN) LTD., AS COLLATERAL AGENT
Reel/Frame 032448/0001 →